Kidney transplantation in a patient with end stage renal disease after complete remission of acute promyelocytic leukemia

J Korean Med Sci. 2012 Jul;27(7):814-7. doi: 10.3346/jkms.2012.27.7.814. Epub 2012 Jun 29.

Abstract

In general, a 2-yr disease-free duration is recommended before kidney transplantation (KT) in end-stage renal disease (ESRD) patients who also have acute leukemia. However, the optimal disease-free interval has not been specified for all subtypes of acute leukemia. Among these subtypes, acute promyelocytic leukemia (APL) shows a favorable prognosis and low relapse rate compared to other types of leukemia. We here report KT after complete remission (CR) of APL in an ESRD patient. Irreversible kidney injury developed in a 23-yr-old man with APL. First, we induced CR and subsequently performed KT 7 months after the achievement of CR. The patient's clinical course after KT was favorable, without allograft rejection or relapse of APL up to 1 yr after KT. On the basis of our clinical experience, it is suggested that a long wait may not be necessary before KT in patients with ESRD and APL.

Keywords: End Stage Renal Disease; Kidney Transplantation; Leukemia, Promyelocytic, Acute.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antineoplastic Agents / therapeutic use
  • Arsenic Trioxide
  • Arsenicals / therapeutic use
  • Bone Marrow Cells / pathology
  • Humans
  • Kidney Failure, Chronic / diagnostic imaging
  • Kidney Failure, Chronic / therapy*
  • Kidney Transplantation*
  • Leukemia, Promyelocytic, Acute / diagnosis*
  • Leukemia, Promyelocytic, Acute / drug therapy
  • Male
  • Oxides / therapeutic use
  • Receptors, Retinoic Acid / genetics
  • Receptors, Retinoic Acid / metabolism
  • Remission Induction
  • Retinoic Acid Receptor alpha
  • Ultrasonography

Substances

  • Antineoplastic Agents
  • Arsenicals
  • Oxides
  • RARA protein, human
  • Receptors, Retinoic Acid
  • Retinoic Acid Receptor alpha
  • Arsenic Trioxide